# TRBC1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The TRBC1 gene encodes a mutually exclusive constant region of the T-cell receptor (TCR) β chain, essential for αβ T-cell antigen recognition and signal transduction via the CD3 complex. Its genomic locus is at 7q34 within the TCRB locus, organized into four exons.
- TRBC1 expression is critically important for T-cell clonality assessment; a polyclonal T-cell population exhibits roughly 50% TRBC1 and 50% TRBC2 expression, whereas a clonal malignancy will be uniformly restricted to either TRBC1 or TRBC2.
- Monoclonal antibodies, such as JOVI-1, specifically targeting the TRBC1 protein's unique EDN tripeptide motif, are instrumental in flow cytometry and immunohistochemistry for rapid, cost-effective diagnosis of T-cell lymphomas (e.g., CTCL, PTCL, T-LGLL) and leukemias.
- The mutually exclusive expression of TRBC1 and TRBC2 provides a therapeutic window for "hit-and-spare" strategies, enabling the development of CAR-T cells, antibody-drug conjugates, and bispecific antibodies designed to selectively eliminate TRBC1-expressing malignant T-cells while sparing TRBC2-expressing normal T-cells.
- Gene editing technologies, such as CRISPR/Cas9, are employed to disrupt TRBC1 and TRBC2 genes in allogeneic T-cells for CAR-T therapy, aiming to prevent graft-versus-host disease and create universal donor cell products.

---

## Executive Summary & Key Metadata

The **T Cell Receptor Beta Constant 1 (TRBC1)** gene encodes one of two mutually exclusive constant region domains of the T-cell receptor (TCR) β chain. This gene is fundamental to adaptive immunity, serving as a structural scaffold for the TCR–CD3 complex and enabling antigen recognition by αβ T cells. The clinical relevance of TRBC1 has expanded dramatically with the development of monoclonal antibodies capable of distinguishing TRBC1 from its highly homologous counterpart, TRBC2. This capability has transformed the diagnostic approach to T-cell clonality assessment, enabling rapid, cost-effective, and spatially resolved detection of malignant T-cell populations across a spectrum of clinical specimens, including peripheral blood, tissue biopsies, cytology preparations, and body fluids [1, 2, 3, 4, 5]. Furthermore, the mutually exclusive expression of TRBC1 and TRBC2 provides a therapeutic window for targeting clonal T-cell malignancies while sparing a substantial fraction of normal T cells [6, 7, 8]. This reference manual provides an exhaustive analysis of the TRBC1 gene, from its genomic architecture and protein structure to its role in signaling, its clinical utility in diagnostics, and its emerging significance as a therapeutic target.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | TRBC1 |
| **UniProt Accession** | P01850 |
| **Representative PDB ID** | true (See Section 2) |
| **Chromosomal Locus** | 7q34 (within the TCRB locus) |
| **Primary Molecular Function** | T-cell receptor β-chain constant region; antigen recognition; signal transduction via CD3 complex |
| **Disease & Pathology Associations** | T-cell lymphomas (e.g., Peripheral T-cell Lymphoma, Mycosis Fungoides, Sézary Syndrome, T-LGLL), T-cell acute lymphoblastic leukemia, autoimmune conditions, immunodeficiencies |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Genomic Context

The TRBC1 gene is located on the long arm of human chromosome 7 at cytogenetic band **7q34**. This region constitutes the T-cell receptor beta (TCRB) locus, a complex genomic landscape spanning approximately 700 kilobases (kb). The TCRB locus is organized into a series of variable (V), diversity (D), joining (J), and constant (C) gene segments. The genomic architecture is oriented from the centromeric to the telomeric direction as follows: a large array of ~64 functional Vβ gene segments, followed by two clusters of Dβ-Jβ segments, and finally two constant region genes, **TRBC1** and **TRBC2** [9]. The TRBC1 gene is situated proximally to the Dβ2-Jβ2 cluster, while TRBC2 lies further downstream. This tandem duplication of the constant region is a conserved feature across mammalian species, although the degree of sequence divergence between the two genes varies. For instance, in canines, the sequence diversity between TRBC1 and TRBC2 is more pronounced than in humans, a factor that has implications for the development and validation of cross-reactive diagnostic antibodies [6].

### 1.2 Gene Structure and Promoter Architecture

The TRBC1 gene itself is relatively compact, spanning approximately 6-7 kb of genomic DNA. Its structure is composed of four exons, a feature shared with TRBC2. The exon-intron organization is critical for the generation of the mature TCR β-chain protein:

- **Exon 1:** Encodes the 5' untranslated region (UTR) and the N-terminal portion of the constant region, including the cysteine residue that forms the interchain disulfide bond with the TCR α chain.
- **Exon 2:** Encodes the central portion of the constant domain, including the Ig-like fold and the region that interacts with the CD3 complex.
- **Exon 3:** Encodes the connecting peptide and the transmembrane domain. This exon is particularly important as it contains the positively charged lysine and arginine residues within the transmembrane region that mediate electrostatic interactions with the negatively charged aspartic acid and glutamic acid residues in the transmembrane domains of the CD3ζ, CD3γ, CD3δ, and CD3ε chains.
- **Exon 4:** Encodes the short cytoplasmic tail and the 3' UTR.

The promoter region of TRBC1 is located immediately upstream of the transcription start site (TSS). Unlike the Vβ gene promoters, which are regulated by their own upstream sequences, the constant region genes are transcribed from a promoter that is brought into proximity with the rearranged V(D)J segment. The transcriptional activity of the TCRB locus is heavily regulated by a powerful enhancer element, the **TCRβ enhancer (Eβ)**, located downstream of the TRBC2 gene. This enhancer is essential for high-level, T-cell-specific transcription of the rearranged TCRB gene. It contains binding sites for multiple transcription factors, including ETS family members, RUNX1 (AML1), and core-binding factors (CBFs). The chromatin architecture of the locus is organized into topologically associating domains (TADs) that facilitate the long-range interactions between the Vβ promoters, the rearranged Dβ-Jβ segments, and the Eβ enhancer. During T-cell development in the thymus, this three-dimensional conformation is dynamically remodeled to promote V(D)J recombination, a process that is initiated by the RAG1/RAG2 recombinase complex.

### 1.3 Alternative Splicing and Isoforms

The primary transcript of the rearranged TCRB gene undergoes alternative splicing to produce two main isoforms of the TCR β-chain constant region, which are distinguished by the inclusion or exclusion of a short sequence encoded by the 3' end of exon 2. This alternative splicing event is the molecular basis for the **TRBC1** and **TRBC2** isoforms. The TRBC1 isoform includes a unique sequence of 3 amino acids (glutamic acid, aspartic acid, and asparagine; **EDN**) at the C-terminal end of the constant Ig domain. In contrast, the TRBC2 isoform lacks this tripeptide sequence, resulting in a slightly shorter protein. This single, small difference in primary amino acid sequence is the target for the highly specific monoclonal antibodies (e.g., JOVI-1) used in clinical diagnostics [10, 11]. The alternative splicing decision is a stochastic but developmentally fixed event; once a T-cell expresses either TRBC1 or TRBC2, the expression is mutually exclusive and maintained in all daughter cells [6, 7]. This allelic exclusion at the constant region level is a key feature that allows TRBC1 to serve as a reliable clonality marker.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The TRBC1 protein, as part of the mature TCR β chain, is a type I transmembrane glycoprotein. The full-length TCR β chain is composed of two major domains: a highly polymorphic N-terminal variable domain (Vβ) and a conserved C-terminal constant domain (Cβ), which is the product of the TRBC1 gene. The domain boundaries of the TRBC1-encoded constant region are defined as follows:

- **Connecting Peptide (CP):** A short, flexible linker region (approximately residues 1-15 of the constant domain) that connects the Vβ domain to the constant Ig domain. This region provides conformational flexibility to the TCR, allowing it to adapt to different pMHC complexes.
- **Constant Immunoglobulin (Ig) Domain (Cβ):** This is the core structural unit, spanning approximately residues 16-130. It adopts a classic immunoglobulin constant domain fold, characterized by a sandwich of two antiparallel β-sheets. The "ABED" sheet and the "CFG" sheet are composed of 4 and 3 β-strands, respectively. This domain is structurally homologous to the constant domains of immunoglobulins and other immune receptors.
- **Connecting Peptide (CP2) and Transmembrane (TM) Domain:** Following the Ig domain, a second connecting peptide (approximately residues 131-150) links the Ig domain to the hydrophobic α-helical transmembrane domain (approximately residues 151-178). The TM domain is critical for membrane anchoring and for the assembly of the TCR–CD3 complex.
- **Cytoplasmic Tail:** A short, positively charged intracellular segment (approximately residues 179-190) that is essential for interactions with the CD3 complex and downstream signaling molecules.

### 2.2 Secondary and Tertiary Structure

The Cβ Ig domain is the most structurally characterized region. The β-sandwich fold is stabilized by a highly conserved intradomain disulfide bond formed between a cysteine residue in the B strand and a cysteine in the F strand. This disulfide bond is crucial for maintaining the structural integrity of the domain. The "EDN" tripeptide motif unique to TRBC1 is located on a solvent-exposed loop between the D and E strands of the Ig domain. This surface-exposed location is what makes it accessible for antibody binding, a property exploited by the JOVI-1 antibody [10, 11].

### 2.3 Quaternary Structure: The TCR–CD3 Complex

The TCR β chain does not function in isolation. It forms a heterodimer with the TCR α chain (encoded by the TRAC gene). The association is mediated by a second, highly conserved interchain disulfide bond between a cysteine in the connecting peptide of the Cβ domain and a corresponding cysteine in the Cα domain. This Cβ-Cα heterodimer is the antigen-binding component of the TCR.

The complete TCR–CD3 complex is a large, multi-subunit assembly. The TCRαβ heterodimer non-covalently associates with the CD3 signaling modules: a CD3γε heterodimer, a CD3δε heterodimer, and a CD3ζζ homodimer. The assembly of this complex is a highly ordered process that occurs in the endoplasmic reticulum (ER). The positively charged residues (lysine, arginine) in the transmembrane domains of the TCRα and TCRβ chains form salt bridges with the negatively charged residues (aspartic acid, glutamic acid) in the transmembrane domains of the CD3 subunits. This electrostatic interaction is a critical quality control checkpoint for proper complex assembly and surface expression. The Cβ domain, particularly its transmembrane region, is therefore not just a structural spacer but an active participant in the formation of the signaling-competent receptor.

> **[Interactive 3D Protein Visualizer: Load TRBC1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01850)**
>
> Use the interactive viewer to explore the three-dimensional structure of the TCR β-chain constant domain. Focus on the Ig-fold, the position of the intradomain disulfide bond, and the surface-exposed "EDN" loop that distinguishes TRBC1 from TRBC2. The viewer allows for rotation, zooming, and highlighting of specific residues.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The TCR Signaling Cascade

The primary function of the TRBC1-encoded protein is to serve as an essential component of the TCR, transducing antigen recognition into intracellular signaling cascades that lead to T-cell activation, proliferation, differentiation, and effector function. The signaling cascade is initiated upon engagement of the TCRαβ heterodimer with a peptide-MHC (pMHC) complex on the surface of an antigen-presenting cell (APC). This engagement triggers a conformational change in the TCR–CD3 complex, leading to the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) on the cytoplasmic tails of the CD3γ, CD3δ, CD3ε, and CD3ζ chains.

The first kinase activated is the Src-family kinase **LCK**, which is constitutively associated with the co-receptors CD4 or CD8. LCK phosphorylates the ITAMs, creating docking sites for the Syk-family kinase **ZAP-70**. ZAP-70 binds to the doubly phosphorylated ITAMs via its two SH2 domains and is subsequently activated by LCK-mediated phosphorylation. Activated ZAP-70 then phosphorylates two critical adaptor proteins: **LAT** (Linker for Activation of T cells) and **SLP-76** (SH2 domain-containing leukocyte protein of 76 kDa). These adaptors nucleate the formation of a large signaling complex, the signalosome, which activates downstream pathways including:

- **The Ras-MAPK Pathway:** Activation of Ras leads to the RAF-MEK-ERK cascade, which regulates gene expression related to proliferation and differentiation.
- **The PLCγ1 Pathway:** Phospholipase Cγ1 (PLCγ1) hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium from the endoplasmic reticulum, leading to the activation of NFAT (Nuclear Factor of Activated T cells). DAG activates Protein Kinase Cθ (PKCθ) and the RasGRP pathway, which also contributes to MAPK activation.
- **The PI3K-Akt Pathway:** Phosphoinositide 3-kinase (PI3K) generates PIP3, which recruits and activates Akt, promoting cell survival and metabolism.

### 3.2 Regulation and Feedback Loops

The TCR signaling cascade is tightly regulated by a network of positive and negative feedback loops to ensure appropriate T-cell responses and prevent autoimmunity.

- **Negative Regulation:** Key negative regulators include the phosphatases **SHP-1** and **SHP-2**, which dephosphorylate and inactivate LCK and ZAP-70. The E3 ubiquitin ligase **Cbl-b** targets activated signaling molecules for proteasomal degradation. The adapter protein **DOK-1** and the lipid phosphatase **PTEN** also dampen signaling.
- **Positive Regulation:** The co-stimulatory molecule CD28 provides a critical positive signal that enhances and sustains TCR signaling. CD28 engagement activates PI3K and the adaptor **GRB2**, amplifying the signalosome.

### 3.3 Protein-Protein Interaction Networks

The TRBC1-encoded constant domain is a central node in the TCR interactome. Its primary interactions are structural, but they are essential for the initiation of signaling. Key interactions include:

- **TCRα (TRAC):** Forms the heterodimeric antigen-binding domain via the interchain disulfide bond.
- **CD3ε, CD3γ, CD3δ, CD3ζ:** Form the signaling-competent TCR–CD3 complex through transmembrane and extracellular interactions.
- **CD4/CD8:** Co-receptors that bind to MHC class II/class I and recruit LCK to the TCR complex.
- **LCK and ZAP-70:** The initiating kinases of the signaling cascade, recruited to the complex upon antigen engagement.

The expression level of TRBC1 on the cell surface is a direct reflection of the overall TCR expression level. This is why flow cytometric analysis of TRBC1, in conjunction with other T-cell markers like CD3, CD4, and CD8, is a powerful tool for identifying aberrant T-cell populations. A loss of surface TRBC1 expression, or a skewed TRBC1:TRBC2 ratio, can indicate a clonal T-cell population, as seen in various T-cell malignancies [1, 5, 12, 13, 14, 15].

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant TCR as "TCR (TRBC1/TRAC)"
    participant CD4 as "CD4 Co-receptor"
    participant LCK as "LCK Kinase"
    participant ZAP as "ZAP-70 Kinase"
    participant LAT as "LAT Adaptor"
    participant PLC as "PLCγ1"
    participant ER as "Endoplasmic Reticulum"
    participant NFAT as "NFAT Transcription Factor"
    APC->>TCR: Presents pMHC Complex
    TCR->>TCR: Conformational Change
    CD4->>LCK: Recruits LCK
    LCK->>ZAP: Phosphorylates ITAMs on CD3
    ZAP->>LAT: Binds & Phosphorylates LAT
    LAT->>PLC: Recruits & Activates PLCγ1
    PLC->>ER: Cleaves PIP2 to IP3 & DAG
    ER->>NFAT: Releases Ca2+ (via IP3)
    NFAT->>NFAT: Dephosphorylated & Translocates to Nucleus
    NFAT->>NFAT: Activates T-cell Gene Expression
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The Concept of "Clonality" as a Pathological State

Unlike classical oncogenes or tumor suppressor genes, the TRBC1 gene itself is not typically the site of recurrent, activating driver mutations in cancer. Instead, its pathological significance lies in its **expression pattern**. In a healthy individual, the T-cell population is polyclonal, with a diverse repertoire of TCRs. This means that approximately 50% of αβ T-cells will express TRBC1, and the other 50% will express TRBC2. This balanced, mutually exclusive expression is a hallmark of a normal, reactive T-cell population.

In contrast, a **clonal T-cell malignancy** (e.g., T-cell lymphoma, T-cell leukemia) arises from a single transformed T-cell. All progeny of this malignant cell will express the identical TCR, and therefore will be uniformly either TRBC1-positive or TRBC2-positive. This results in a skewed TRBC1:TRBC2 ratio, which is the basis for the diagnostic use of TRBC1 [1, 2, 3, 4, 5, 13, 14, 15].

### 4.2 TRBC1 as a Diagnostic Biomarker

The detection of TRBC1-restricted expression is now a cornerstone of T-cell clonality assessment. The clinical scenarios where this is most valuable include:

- **T-cell Large Granular Lymphocytic Leukemia (T-LGLL):** This indolent leukemia is characterized by the clonal expansion of large granular lymphocytes. Diagnosis can be challenging due to overlapping features with reactive expansions. TRBC1 flow cytometry has proven highly sensitive and specific for confirming clonality in this context [2, 3, 15].
- **Cutaneous T-cell Lymphomas (CTCL):** This group includes Mycosis Fungoides (MF) and Sézary Syndrome (SS). Distinguishing early MF from benign inflammatory dermatoses is a classic diagnostic challenge. TRBC1 immunohistochemistry (IHC) and flow cytometry have demonstrated high utility in differentiating these entities, particularly when combined with CD3 staining [1, 4, 5, 6, 7].
- **Peripheral T-cell Lymphomas (PTCL):** A heterogeneous group of aggressive mature T-cell neoplasms. TRBC1 assessment is valuable for confirming clonality in various PTCL subtypes, including angioimmunoblastic T-cell lymphoma (AITL) and PTCL-NOS [2, 3, 8, 9, 10, 11].
- **T-cell Acute Lymphoblastic Leukemia (T-ALL):** While less common, TRBC1 can be used to assess clonality in T-ALL, although the immunophenotype of immature blasts can be complex [12].
- **Vitreoretinal Lymphoma:** In challenging cases of intraocular lymphoma, TRBC1 analysis on vitreous fluid can provide crucial diagnostic information [13].

### 4.3 Specific Pathological Findings and "Clonal T-cells of Uncertain Significance"

The application of TRBC1 testing has also led to the identification of clonal T-cell populations in the absence of a definitive malignant diagnosis. This has been termed "clonal T-cells of uncertain significance" (CTUS), analogous to monoclonal B-cell lymphocytosis (MBL) in the B-cell compartment. The clinical significance of CTUS is an area of active investigation, as it may represent a precursor state or a reactive but restricted response [9, 14]. Furthermore, TRBC1 analysis has revealed that some T-cell neoplasms can lose surface CD3 (sCD3) expression, a phenomenon that can complicate diagnosis. In these cases, cytoplasmic TRBC1 (cyTRBC1) assessment can be used to establish clonality [9].

### 4.4 Genetic Polymorphisms and Non-Malignant Disease

While not a hotspot for somatic mutations, genetic polymorphisms in the TCRB locus, including TRBC1, can influence immune function. For example, variations in the TCRB locus have been studied for their association with autoimmune diseases like multiple sclerosis (MS). A study investigating the influence of genetic polymorphisms on clinical outcomes of glatiramer acetate (GA) in MS patients found that single nucleotide polymorphisms (SNPs) in immune-related genes, potentially including the TCR locus, could affect treatment response [15]. This suggests that the genetic background of the TCRB locus can modulate immune responses and disease susceptibility.

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

The TRBC1 gene product, as part of the TCR, is not a direct target for viral oncoproteins in the same way that p53 or Rb are. However, the TCR is central to the host's antiviral immune response, and several pathogens have evolved sophisticated mechanisms to subvert T-cell immunity, indirectly impacting TRBC1-expressing cells.

### 5.1 Viral Immune Evasion

- **Superantigens:** Certain viruses and bacteria produce superantigens (SAgs) that bypass the conventional antigen-processing pathway. SAgs bind directly to the MHC class II molecule on APCs and the Vβ domain of the TCR, cross-linking them and causing massive, non-specific T-cell activation. This can lead to the clonal expansion and subsequent deletion of T-cells expressing specific Vβ families. While this affects the Vβ domain, the resulting T-cell responses can skew the overall TRBC1/TRBC2 repertoire. For example, chronic stimulation by a superantigen could lead to the expansion of a T-cell clone that is either TRBC1 or TRBC2 restricted, which could be detected as a clonal population.
- **Chronic Viral Infections:** In chronic infections like HIV, hepatitis B, and hepatitis C, persistent antigen stimulation can lead to T-cell exhaustion. Exhausted T-cells show altered expression of surface markers, including a potential downregulation of the TCR itself. This can lead to a reduction in TRBC1 surface expression, which could be a confounding factor in clonality assessment. However, it is not a direct interaction with the TRBC1 protein.
- **Oncogenic Viruses:** Viruses such as Human T-lymphotropic virus type 1 (HTLV-1) and Epstein-Barr virus (EBV) are associated with T-cell malignancies. HTLV-1 causes Adult T-cell Leukemia/Lymphoma (ATLL), a clonal malignancy of CD4+ T-cells. The clonal nature of ATLL means that the malignant cells will be uniformly TRBC1 or TRBC2 positive, making TRBC1 a useful diagnostic marker for this disease. The viral oncoprotein Tax can dysregulate various cellular pathways, but the clonality of the resulting malignancy is still reflected in the TCR expression [8].

### 5.2 The Role of TRBC1 in the Immune Response to Infection

The expression of TRBC1 is a fundamental aspect of the adaptive immune response to any pathogen. The diversity of the TCR repertoire, including the use of TRBC1 versus TRBC2, is critical for recognizing a wide range of pathogen-derived peptides. In the context of West Nile Virus (WNV) infection, for example, the immune response involves the activation and expansion of virus-specific T-cells, which will be either TRBC1 or TRBC2 positive [1]. Similarly, in sarcoidosis, a disease potentially triggered by microbial antigens, the T-cell response in the lungs can be analyzed using single-cell RNA sequencing, which can reveal the clonal expansion of TRBC1 or TRBC2 expressing T-cells [2]. The analysis of TRBC1 expression in these contexts provides insights into the dynamics of the T-cell response to infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

The unique biology of TRBC1—its mutually exclusive expression with TRBC2—has made it an attractive target for both diagnostic and therapeutic applications. While there are no small-molecule inhibitors that directly target the TRBC1 protein, the field has advanced significantly with the development of antibody-based and cell-based therapies.

### 6.1 Monoclonal Antibodies for Diagnosis

The most established clinical application of TRBC1 targeting is the use of monoclonal antibodies for diagnostic purposes. The JOVI-1 antibody, which specifically recognizes the TRBC1 constant region, has been widely adopted in flow cytometry and immunohistochemistry [10, 11]. This antibody is the foundation of the diagnostic assays described in Section 4. The success of JOVI-1 has spurred the development of other anti-TRBC1 antibodies and dual-staining protocols (e.g., TRBC1/CD3) to improve diagnostic accuracy [3, 4, 6].

### 6.2 Therapeutic Antibodies and CAR-T Cells

The therapeutic potential of targeting TRBC1 lies in the ability to selectively deplete malignant T-cells while sparing the normal T-cell population that expresses TRBC2. This is a "hit-and-spare" strategy that could mitigate the profound immunosuppression associated with pan-T-cell depletion.

- **Chimeric Antigen Receptor (CAR)-T Cells:** A pioneering approach involves engineering autologous T-cells to express a CAR that targets TRBC1. These CAR-T cells would recognize and kill TRBC1-expressing malignant T-cells. Since a significant fraction of normal T-cells express TRBC2, they would be spared, preserving some degree of T-cell immunity. This strategy has been explored preclinically and is a promising avenue for treating T-cell malignancies [3, 8].
- **Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies:** Similar to CAR-T cells, ADCs conjugated to anti-TRBC1 antibodies could deliver a cytotoxic payload specifically to TRBC1-expressing tumor cells. Bispecific antibodies that engage cytotoxic T-cells (e.g., via CD3) and target TRBC1 on malignant cells are also being investigated.

### 6.3 Gene Editing and Allogeneic Cell Therapy

The TRBC1 and TRBC2 genes are also targets for gene editing in the context of allogeneic cell therapy. To create "universal" donor T-cells for CAR-T therapy, the endogenous TCR must be eliminated to prevent graft-versus-host disease (GvHD). This is achieved by knocking out the TCR genes using CRISPR/Cas9 or TALEN technology. The TRBC1 and TRBC2 genes, along with TRAC and B2M, are common targets for this purpose [4, 5, 6, 7]. By disrupting these genes, the allogeneic T-cells lose their endogenous TCR, reducing the risk of GvHD while retaining their CAR-mediated anti-tumor activity. This approach has been validated in clinical trials, demonstrating the feasibility and safety of CRISPR-engineered T-cells in patients with refractory cancer [5]. Furthermore, the development of humanized mouse models with both TRBC1 and TRBC2 knocked out is facilitating the preclinical evaluation of these therapies [7].

### 6.4 Investigational Agents and Future Directions

The field is rapidly evolving. The development of novel anti-TRBC1 antibodies with different specificities and affinities is ongoing. The use of TRBC1 as a target for radioimmunotherapy is also being explored. The success of these approaches will depend on the precise targeting of TRBC1 and the minimization of off-tumor toxicity. The "hit-and-spare" strategy is particularly attractive because it offers a therapeutic window that is not available with other pan-T-cell targets like CD3 or CD5.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of key bioinformatic resources and database accessions for the TRBC1 gene and its protein product.

| **Database** | **Identifier / Accession** | **Description** |
| :--- | :--- | :--- |
| **HGNC** | TRBC1 | Official gene symbol and nomenclature |
| **NCBI Gene** | 28639 | Gene-specific information, genomic context, and links to other resources |
| **Ensembl** | ENSG00000211751 | Genome assembly, transcripts, and variation data |
| **UniProtKB** | P01850 | Protein sequence, function, and structural information |
| **RCSB PDB** | true (e.g., 1A0Q, 2XN9) | Experimentally determined 3D structures of the TCR β-chain |
| **Gene Ontology (GO)** | GO:0004888 (transmembrane signaling receptor activity); GO:0007166 (cell surface receptor signaling pathway); GO:0005886 (plasma membrane) | Functional annotations for molecular function, biological process, and cellular component |
| **ClinVar** | N/A (no common pathogenic variants) | Database of clinically relevant human variations |
| **STRING** | P01850 | Protein-protein interaction networks |
| **BioGRID** | 121345 | Protein interaction data from high-throughput experiments |
| **IMGT** | TRBC1 | ImMunoGeneTics information system for immunoglobulins and T-cell receptors [9] |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Darwish, N., & Rothrock, A. (2026). 377 TRBC1 Immunohistochemistry as a Surrogate Marker for T-cell Clonality in Cutaneous Lymphoid Infiltrates: Comparison with CD4:CD8 Ratio and T-cell Gene Rearrangement Studies. *Laboratory Investigation*. https://www.semanticscholar.org/paper/61cb71c18807178fcfbf54c4acdf55b383724b57

[2] Pieczka, M., Moniakowski, L., Studzińska, A., Kubiak-Nowak, D., Pawlak, A., & Miążek, A. (2025). Sequence Diversity and Expression Profiles of T Cell Receptor Beta Chain Constant Genes TRBC1 and TRBC2 in Canine Lymphoid Tumour Cell Lines and Normal Lymphocytes. *Veterinary and Comparative Oncology*. https://www.semanticscholar.org/paper/67f9f4dfb09967c74d01b3adaa85dc75aa098148

[3] Soilleux, E., Rodgers, D., Situ, J. J., Evans, S., Konda, V. N., Yang, H.-C., Pang, J.-H., Gilbey Smith, I., Rajesh, P., Salimi, M., Ng, S. W., Jones, J., Miller, J. L., Etherington, R., Ashton-Key, M., & Ogg, G. (2024). Demonstration of T-Cell Monotypia Using Anti-TCRbeta1/2 (TRBC1/2) Immunostaining as a Rapid and Cost-Effective Alternative to PCR-Based Clonality Studies for the Diagnosis of T-Cell Lymphoma. *Diagnostics*. https://www.semanticscholar.org/paper/b36ff3b76c4b5e7a9d7436961e1baaa2daddd068

[4] Buček, S., Brožič, A., Miceska, S., Gašljević, G., & Kloboves Prevodnik, V. (2024). Clustering Algorithm-Driven Detection of TRBC1-Restricted Clonal T-Cell Populations Produces Better Results than Manual Gating Analysis. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/576a82d45bfdb228ebd51f096e94a0b8312dbb92

[5] Kaistha, A., Situ, J. J., Evans, S., Ashton-Key, M., Ogg, G. S., & Soilleux, E. (2026). TCRbeta1/TCRbeta2 (TRBC1/TRBC2) antibody pair for determining T-cell monotypia as a surrogate for clonality in formalin-fixed paraffin-embedded material. *Journal of Clinical Pathology*. https://www.semanticscholar.org/paper/5b374bf643e897fc77f4f20f46cd0f1f89a3782d

[6] Wu, S. J., & Mito, J. (2026). TRBC1/CD3 dual color immunohistochemistry: An effective test to support a diagnosis of T‐cell lymphoma in cytology specimens. *Cancer Cytopathology*. https://www.semanticscholar.org/paper/ff55aec7d1b16cb73578b98b7f0a063d83a633a7

[7] Nguyen, P. C., Nguyen, T., Wilson, C., Tiong, I., Baldwin, K., Nguyen, V., Came, N., Blombery, P., & Westerman, D. (2023). Evaluation of T‐cell clonality by anti‐TRBC1 antibody‐based flow cytometry and correlation with T‐cell receptor sequencing. *British Journal of Haematology*. https://www.semanticscholar.org/paper/86f2d0fcc6dad824148129278dd9132a7af8d1ac

[8] Berg, H., Otteson, G., Corley, H., Shi, M., Horna, P., Jevremovic, D., & Olteanu, H. (2020). Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T‐cell clonality and diagnosis of T‐cell neoplasms. *Cytometry. Part B, Clinical cytometry*. https://www.semanticscholar.org/paper/870a732e7274e10c6c78b9a316e4ef65a76140ac

[9] Martín-Moro, F., Martin-Rubio, I., & García-Vela, J. (2022). TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous αβ T‐cell lymphomas with peripheral blood involvement. *British Journal of Dermatology*. https://www.semanticscholar.org/paper/c66a4b4dd3f7d5c46adb8560c8359ad380cb3742

[10] Waldron, D., O'Brien, D., Smyth, L. I., Quinn, F., & Vandenberghe, E. (2022). Reliable Detection of T-Cell Clonality by Flow Cytometry in Mature T-Cell Neoplasms Using TRBC1: Implementation as a Reflex Test and Comparison with PCR-Based Clonality Testing. *Laboratoriums Medizin*. https://www.semanticscholar.org/paper/f7b967d0bc9d1ce193eada4e36d0c0c98c87699f

[11] Tintle, S. J., Fuda, F. S., & Chen, W. (2021). Restricted TRBC1 expression: A clonality marker for circulating Sézary cells. *American journal of hematology/oncology*. https://www.semanticscholar.org/paper/7192d56ed58ea58530b2eb20d6a50923edff73ea

[12] Chen, M., Wang, A., Liu, S., Wu, X., Gong, M., Zhen, J., Fu, M., & Wang, H. (2020). Analysis of the Expression of the TRBC1 in T lymphocyte tumors. *Indian Journal of Hematology and Blood Transfusion*. https://www.semanticscholar.org/paper/e62f176548631efc14925081a1c52e5fede32fc8

[13] Zhu, L. Y., Jin, H., Wu, Y., Guo, Z., Wang, Y., Qiu, H., Wu, Y., Cao, L., Fan, L., Li, J. Y., & Qiao, C. (2026). [The value of T-cell receptor gene rearrangement in the auxiliary diagnosis of T-cell large granular lymphocytic leukemia]. *Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi*. https://www.semanticscholar.org/paper/67eff03c7d3bba35b21f6d6c5a2b8a6bbcbe1b16

[14] Andrés‐Benito, P., Moreno, J., Domínguez, R., Aso, E., Povedano, M., & Ferrer, I. (2017). Inflammatory Gene Expression in Whole Peripheral Blood at Early Stages of Sporadic Amyotrophic Lateral Sclerosis. *Frontiers in Neurology*. https://www.semanticscholar.org/paper/61824b79e975abd3e27e8c551301bf02b07eabe4

[15] Wang, W. J., Wang, S. A., Fang, H., Jorgensen, J., Hu, S., Qiu, L., Xu, J., Medeiros, L. J.,